By Ted Bosworth
Orlando, Fla.—An investigational monoclonal antibody called sutimlimab was found to be effective in controlling the hemolytic anemia that characterizes cold agglutinin disease (CAD) in a pivotal phase 3 trial.
The novel treatment binds to complement component 1 (C1), thereby preventing hemolytic anemia in patients with CAD, an autoimmune disorder.